All In Biotech

NDA 200603 · Sunovion Pharms INC

Latuda

Lurasidone Hydrochloride · Oral

Novel

Last checked: Nov 20, 2026Latest source record: Jan 22, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 28, 2010

Approved uses

7

Original approval plus efficacy supplements

Registered trials

85

41 Phase 3, 4 recruiting

FAERS reports

20,965

9,380 serious, 581 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS; and SUICIDAL THOUGHTS AND BEHAVIORS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. LATUDA is not approved for the treatment of patients with dementia-related psychosis ( 5.1 ). Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients. Closely monitor for clinical worsening and emergence of suicidal thoughts and behaviors ( 5.2 ). Increased Mortality in Elderly Patients with Dementia-Related Psychosis Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of...

What it is approved for

From the label in effect Jan 31, 2025.

LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . LATUDA is an atypical antipsychotic indicated for the treatment of: Schizophrenia in adults and adolescents (13 to 17 years) ( 1 , 14.1 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults and pediatric patients (10 to 17 years) as monotherapy ( 1 , 14.2 ) Depressive episode associated with Bipolar I Disorder (bipolar depression) in adults as adjunctive therapy with lithium or valproate ( 1 , 14.2 )

Mechanism: The mechanism of action of lurasidone in the treatment of schizophrenia and bipolar depression is unclear. However, its efficacy in schizophrenia and bipolar depression could be mediated through a combination of central dopamine D 2 and serotonin Type 2 (5HT 2A ) receptor antagonism.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

5 products under this application
  • LATUDA · LURASIDONE HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
  • LATUDA · LURASIDONE HYDROCHLORIDE 80MG · TABLET, ORAL · Prescription · TE AB
  • LATUDA · LURASIDONE HYDROCHLORIDE 60MG · TABLET, ORAL · Prescription · TE AB
  • LATUDA · LURASIDONE HYDROCHLORIDE 20MG · TABLET, ORAL · Prescription · TE AB
  • LATUDA · LURASIDONE HYDROCHLORIDE 40MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Lurasidone" as an intervention, any sponsor and status, largest first.

All 85 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use2,089
  • drug ineffective1,897
  • anxiety1,241
  • feeling abnormal1,170
  • depression1,146
  • weight increased1,104
  • somnolence1,081
  • nausea1,061
  • insomnia1,016
  • suicidal ideation1,011
  • fatigue954
  • dyskinesia832

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20091
20101
2011102
2012234
2013229
2014413
2015745
20161,036
20172,654
20182,711
20193,110
20202,319
20212,827
20221,830
20231,066
2024740
2025545
2026402

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Latuda (Lurasidone HCl)

2024 spending

$39.6M

Beneficiaries

6,273

24,193 claims

Per beneficiary

$6,320

$48.06 per unit

View as table
YearSpending
2020$1,316,735,101
2021$1,366,288,474
2022$1,448,336,647
2023$455,168,823
2024$39,642,924

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 200 on PubMed

Sponsor: Sunovion Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.